Eisai Co., Ltd. (ESALY) Income Statement Analysis

See more : Gracell Biotechnologies Inc. (GRCL) Income Statement Analysis – Financial Results

Complete financial analysis of Eisai Co., Ltd. (ESALY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eisai Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

Eisai Co., Ltd. (ESALY)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.eisai.co.jp

About Eisai Co., Ltd.

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Revenue	756.23B	645.94B	695.62B	642.83B	600.05B	539.10B	547.92B	548.47B	600.35B	573.68B	647.93B	768.93B	803.14B	781.71B	734.42B	674.18B	601.26B	533.14B	500.13B	466.61B	431.75B	361.71B	302.47B
Cost of Revenue	174.83B	161.31B	175.69B	184.49B	201.25B	195.91B	194.46B	193.60B	188.16B	174.11B	173.35B	167.78B	160.73B	152.41B	118.94B	109.37B	104.51B	98.61B	97.18B	102.47B	101.57B	98.60B	91.68B
Gross Profit	581.40B	484.63B	519.93B	458.34B	398.80B	343.19B	353.46B	354.87B	412.20B	399.57B	474.57B	601.15B	642.41B	629.29B	615.48B	564.81B	496.75B	434.53B	402.95B	364.15B	330.18B	263.11B	210.79B
Gross Profit Ratio	76.88%	75.03%	74.74%	71.30%	66.46%	63.66%	64.51%	64.70%	68.66%	69.65%	73.24%	78.18%	79.99%	80.50%	83.81%	83.78%	82.62%	81.50%	80.57%	78.04%	76.47%	72.74%	69.69%
Research & Development	171.74B	150.30B	140.12B	144.84B	139.58B	112.48B	122.31B	131.91B	0.00	0.00	0.00	0.00	0.00	0.00	225.43B	108.30B	93.25B	78.33B	69.02B	59.70B	55.04B	49.61B	46.70B
General & Administrative	366.43B	281.40B	256.30B	228.21B	183.86B	179.68B	192.82B	194.55B	0.00	0.00	0.00	0.00	0.00	0.00	372.30B	351.25B	307.80B	269.39B	250.87B	228.44B	202.46B	154.66B	127.05B
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	366.43B	281.40B	256.30B	228.21B	183.86B	179.68B	192.82B	194.55B	0.00	0.00	0.00	0.00	0.00	0.00	372.30B	351.25B	307.80B	269.39B	250.87B	228.44B	202.46B	154.66B	127.05B
Other Expenses	-10.52B	1.17B	-1.99B	-866.00M	-1.85B	-8.03B	-13.60B	80.00M	341.09B	329.10B	378.82B	488.03B	556.00B	537.48B	1.00M	0.00	0.00	0.00	0.00	1.00M	0.00	-130.00M	-96.00M
Operating Expenses	527.65B	432.87B	394.43B	372.19B	321.59B	284.13B	301.53B	326.53B	341.09B	329.10B	378.82B	488.03B	556.00B	537.48B	597.73B	459.55B	401.04B	347.72B	319.88B	288.15B	257.49B	204.14B	173.66B
Cost & Expenses	702.48B	594.18B	570.12B	556.68B	522.84B	480.03B	495.99B	520.13B	529.25B	503.21B	552.17B	655.81B	716.73B	689.90B	716.67B	568.91B	505.55B	446.33B	417.06B	390.62B	359.06B	302.75B	265.34B
Interest Income	2.40B	2.15B	4.02B	4.86B	2.56B	1.85B	2.02B	2.43B	963.00M	1.12B	815.00M	997.00M	1.25B	3.17B	5.33B	5.12B	3.35B	1.70B	1.34B	1.47B	2.78B	0.00	0.00
Interest Expense	1.69B	1.36B	1.46B	1.56B	2.97B	3.24B	3.49B	4.89B	5.55B	6.69B	6.89B	7.42B	7.66B	7.63B	762.00M	65.00M	79.00M	52.00M	28.00M	56.00M	296.00M	687.00M	1.13B
Depreciation & Amortization	38.40B	36.30B	33.70B	26.84B	26.18B	26.48B	34.06B	38.94B	48.52B	51.09B	48.69B	51.26B	57.37B	58.63B	34.40B	26.80B	24.99B	22.45B	18.49B	15.33B	15.33B	15.00B	15.14B
EBITDA	96.79B	89.85B	162.53B	114.76B	103.37B	84.51B	87.91B	69.51B	112.05B	128.94B	149.81B	160.86B	138.78B	136.08B	55.34B	136.68B	120.71B	109.80B	101.59B	27.81B	78.52B	58.65B	13.34B
EBITDA Ratio	12.80%	13.91%	23.36%	17.85%	17.23%	15.68%	16.04%	12.67%	18.66%	22.48%	23.12%	20.92%	17.28%	17.41%	7.53%	20.27%	20.08%	20.60%	20.31%	5.96%	18.19%	16.21%	4.41%
Operating Income	58.39B	51.77B	125.50B	86.15B	77.21B	59.06B	51.94B	28.34B	71.11B	70.46B	95.75B	113.12B	86.41B	91.81B	17.75B	105.26B	95.70B	86.81B	83.06B	75.86B	72.69B	58.97B	37.13B
Operating Income Ratio	7.72%	8.01%	18.04%	13.40%	12.87%	10.96%	9.48%	5.17%	11.84%	12.28%	14.78%	14.71%	10.76%	11.74%	2.42%	15.61%	15.92%	16.28%	16.61%	16.26%	16.84%	16.30%	12.28%
Total Other Income/Expenses	-3.93B	785.00M	2.56B	3.30B	-409.00M	-1.40B	-1.46B	-2.46B	-12.89B	966.00M	-1.10B	-10.55B	-12.13B	-21.32B	-96.00M	5.07B	378.00M	845.00M	-539.00M	-6.04B	-9.93B	-16.13B	-11.60B
Income Before Tax	54.46B	52.55B	128.06B	89.45B	76.80B	57.67B	50.47B	25.88B	58.21B	71.43B	94.65B	102.57B	74.28B	70.48B	17.65B	110.33B	96.08B	87.65B	82.52B	69.83B	62.75B	42.84B	25.54B
Income Before Tax Ratio	7.20%	8.14%	18.41%	13.92%	12.80%	10.70%	9.21%	4.72%	9.70%	12.45%	14.61%	13.34%	9.25%	9.02%	2.40%	16.37%	15.98%	16.44%	16.50%	14.96%	14.53%	11.84%	8.44%
Income Tax Expense	8.74B	10.07B	5.60B	22.97B	22.38B	15.42B	-4.57B	-17.58B	25.03B	22.88B	35.71B	34.79B	33.41B	22.13B	37.19B	39.20B	32.23B	31.80B	32.93B	-28.61B	26.10B	19.63B	-14.20B
Net Income	45.72B	42.12B	121.77B	63.39B	51.85B	39.36B	54.93B	43.25B	32.96B	48.28B	58.51B	67.39B	40.34B	47.68B	-17.01B	70.61B	63.41B	55.51B	50.15B	41.03B	36.80B	23.32B	11.28B
Net Income Ratio	6.05%	6.52%	17.50%	9.86%	8.64%	7.30%	10.03%	7.89%	5.49%	8.42%	9.03%	8.76%	5.02%	6.10%	-2.32%	10.47%	10.55%	10.41%	10.03%	8.79%	8.52%	6.45%	3.73%
EPS	159.44	146.94	424.77	221.12	180.97	137.63	192.50	151.67	115.56	169.38	205.33	236.52	141.58	167.35	-59.80	238.10	221.81	194.22	174.26	138.34	126.14	78.67	38.03
EPS Diluted	159.44	146.94	424.77	221.12	180.97	137.42	192.25	151.53	115.46	169.31	205.31	236.51	141.56	167.30	-59.80	238.10	221.81	194.22	174.26	138.34	126.14	78.67	38.03
Weighted Avg Shares Out	286.73M	286.65M	286.66M	286.66M	286.48M	285.98M	285.37M	285.17M	285.17M	285.01M	284.97M	284.94M	284.91M	284.90M	284.49M	296.57M	285.87M	285.79M	287.78M	296.57M	291.72M	296.45M	296.45M
Weighted Avg Shares Out (Dil)	286.73M	286.65M	286.66M	286.66M	286.48M	286.42M	285.75M	285.44M	285.42M	285.13M	284.99M	284.95M	284.95M	284.99M	284.49M	296.57M	285.87M	285.79M	287.78M	296.57M	291.72M	296.45M	296.45M

EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE

November 29, 2022prnewswire.com

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of...

UTHR vs. ESALY: Which Stock Is the Better Value Option?

November 28, 2022zacks.com

UTHR vs. ESALY: Which Stock Is the Better Value Option?

EISAI TO PRESENT LATEST DATA ON FYCOMPA® (PERAMPANEL) CIII AT THE 76TH AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING

November 23, 2022prnewswire.com

EMBARGOED UNTIL DECEMBER 2, 2022 NUTLEY, N.J. , Nov. 23, 2022 /PRNewswire/ -- Eisai Co., Ltd.

EISAI TO PRESENT FULL FINDINGS FROM LECANEMAB CONFIRMATORY PHASE 3 CLINICAL TRIAL (CLARITY AD) AND OTHER ALZHEIMER'S DISEASE RESEARCH AT THE 15TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE

November 20, 2022prnewswire.com

TOKYO , Nov. 20, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker findings from the company's Phase 3 confirmatory Clarity AD clinical trial for lecanemab (development code: BAN2401), an...

Eisai Co., Ltd. (ESALF) Q2 2022 Earnings Call Transcript

November 7, 2022seekingalpha.com

Eisai Co., Ltd. (OTCPK:ESALF) Q2 2022 Earnings Conference Call November 7, 2022 2:00 AM ET Company Participants Haruo Naito - Representative Corporate Officer and Chief Executive Officer Ivan Cheung - Senior Vice President, Global Alzheimer's Disease Officer, President, Americas Region...